Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 13 for:    Advaxis

Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02853604
Recruitment Status : Active, not recruiting
First Posted : August 3, 2016
Last Update Posted : March 5, 2019
Sponsor:
Collaborator:
Gynecologic Oncology Group
Information provided by (Responsible Party):
Advaxis, Inc.

Brief Summary:

High-risk locally advanced carcinoma of the cervix (HRLACC) following concurrent chemotherapy and radiation therapy. This is a group of patients with a significant unmet need. The estimated probability of disease recurrence or death within 4 years of diagnosis is 50% and the prognosis is very grave for those who experience a recurrence.

The purpose of the study is to compare the disease free survival (DFS) of ADXS11-001 to placebo administered following CCRT with curative intent in subjects with HRLACC.


Condition or disease Intervention/treatment Phase
High Risk Cervical Cancer Advanced Cervical Cancer Drug: ADXS11-001 Drug: Placebo Phase 3

Detailed Description:

This is a double-blind, placebo-controlled randomized study of ADXS11 001 administered in the adjuvant setting after completion of cisplatin-based CCRT in subjects with locally advanced cervical cancer at higher risk for recurrence (HRLACC), or death. All eligible subjects will have received CCRT administered with curative intent according to institutional/national guidelines as well as meeting the minimum standards defined in the protocol. Subjects must initiate the Screening period within 10 weeks after the completion of CCRT. Baseline radiographic assessments and clinical laboratory assessments must be completed no longer than 28 days prior to and 3 days prior to the first study treatment infusion, respectively. Eligible subjects will be randomized 1:2 to receive either placebo or ADXS11-001. Subjects will receive 1 infusion of study treatment administered every 3 weeks for 3 doses for the first 3 months. Thereafter, subjects will receive study treatment every 8 weeks for a total of 5 doses or until disease recurrence. Subjects will receive a 7-day course of an oral antibiotic or placebo starting 72 hours following the completion of study treatment administration.

An interim analysis will be performed when there is at least one-half the number of DFS events required for full maturity of the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Study Start Date : September 2016
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : October 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arm Intervention/treatment
Placebo Comparator: Reference Treatment Group (Arm A)
Placebo Arm A
Drug: Placebo
Experimental: Experimental Treatment Group (Arm B)

ADXS11-001

1:2 Arm A to Arm B

Drug: ADXS11-001



Primary Outcome Measures :
  1. Disease free survival (DFS) [ Time Frame: 5 Years ]
    To compare the disease free survival (DFS) of ADXS11-001 to placebo administered in the adjuvant setting following concurrent chemotherapy and radiotherapy (CCRT) administered with curative intent to subjects with high-risk locally advanced squamous, adenosquamous, or adenocarcinoma of the cervix (HRLACC).


Secondary Outcome Measures :
  1. Safety & tolerability Overall survival (OS) [ Time Frame: 5 Years ]
    To determine and compare the frequency and severity of adverse events (AEs) as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 for the regimens administered on this study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have a biopsy confirmed diagnosis of squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix. Histologic confirmation of the original primary tumor is required.
  • Subjects must have received definitive therapy with curative intent, which consist of at least 4 weeks of treatment with cisplatin and a minimum of 40Gy external beam radiation therapy (EBRT).
  • Have performance status of 0 or 1 on the GOG performance scale
  • Demonstrate adequate organ function

Exclusion Criteria:

  • Has not achieved disease-free status after completion of CCRT administered with curative intent.
  • Has FIGO Stage IVB
  • Has histologies other than squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix.
  • Has implanted medical device(s) that pose a high risk for colonization and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous implant(s)).
  • Has a contraindication (sensitivity or allergy) to trimethoprim/sulfamethoxazole and ampicillin.
  • Has undergone a previous hysterectomy defined as removal of the entire uterus or will have a hysterectomy as part of their initial cervical cancer therapy. NOTE: Women who have had a partial/subtotal hysterectomy are eligible to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02853604


  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
Mobile, Alabama, United States
United States, Arizona
Site
Phoenix, Arizona, United States
Phoenix, Arizona, United States
United States, California
Duarte, California, United States
Long Beach, California, United States
Site
Orange, California, United States, 92868
Orange, California, United States
Site
San Francisco, California, United States
United States, Florida
Site
Miami, Florida, United States
Site
Tallahassee, Florida, United States
Tampa, Florida, United States
United States, Georgia
Augusta, Georgia, United States
United States, Illinois
Maywood, Illinois, United States
Site
Park Ridge, Illinois, United States
United States, Indiana
Site
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
United States, Iowa
Iowa City, Iowa, United States
United States, Maine
Scarborough, Maine, United States
United States, Maryland
Site
Baltimore, Maryland, United States
United States, Michigan
Detroit, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Nebraska
Site
Omaha, Nebraska, United States
United States, Nevada
Site
Las Vegas, Nevada, United States
United States, New Jersey
Site
Hackensack, New Jersey, United States
Site
Newark, New Jersey, United States, 07103
United States, New York
Albany, New York, United States, 12208
Site
Brooklyn, New York, United States
United States, North Carolina
Charlotte, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Ohio
Site
Cincinnati, Ohio, United States, 45219
Site
Hilliard, Ohio, United States
Kettering, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, South Carolina
Greenville, South Carolina, United States
United States, Tennessee
Chattanooga, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Site
Dallas, Texas, United States
Site
Galveston, Texas, United States
Houston, Texas, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Argentina
Site
La Rioja, Argentina, F5300 COE
Brazil
Site
Rio De Janeiro, RJ, Brazil, 20220-410
Site
Natal, RN, Brazil, 59075-740
Canada, Alberta
SITE
Calgary, Alberta, Canada, T2N4N2
Canada, Quebec
SITE
Montréal, Quebec, Canada, H2X0A9
Site
Sherbrooke, Quebec, Canada, J1H5N4
Chile
SITE
Temuco, Araucania, Chile, 4810469
SITE
Santiago de Chile, Region Metropolitana, Chile, 7500836
Korea, Republic of
Site
Seongnam, Korea, Republic of, 13496
Site
Seoul, Korea, Republic of, 1812
Site
Seoul, Korea, Republic of, 3080
Site
Seoul, Korea, Republic of, 3722
Site
Seoul, Korea, Republic of, 5505
Site
Seoul, Korea, Republic of, 6273
Site
Seoul, Korea, Republic of, 6351
Site
Yangsan, Korea, Republic of, 50612
Malaysia
Site
Kota Bharu, Kelantan, Malaysia, 15586
Site
Kota Bharu, Kelantan, Malaysia, 16150
Site
Ampang, Selangor, Malaysia, 68000
Site
Kuala Lumpur, Malaysia, 59100
Site
Pulau Pinang, Malaysia, 13200
Mexico
Site
Mexico City, D.f., Mexico, CP 06760
Site
Chihuahua, Mexico, 31217
Poland
Site
Białystok, Poland, 15-027
Site
Lublin, Poland, 20-090
Russian Federation
Site
Krasnodar, Krasnodar Region, Russian Federation, 350040
Site
Arkhangel'sk, Russian Federation, 163045
Site
Moscow, Russian Federation, 115478
Site
Nal'chik, Russian Federation, 360000
Site
Nizhny Novgorod, Russian Federation, 603006
Site
Obninsk, Russian Federation, 249036
Site
Orenburg, Russian Federation, 460021
Site
Pyatigorsk, Russian Federation, 357502
Site
Rostov-on-Don, Russian Federation
Site
Saint Petersburg, Russian Federation, 197758
Site
Saint Petersburg, Russian Federation, 198255
Site
Sochi, Russian Federation, 354057
Site
Ufa, Russian Federation, 450054
Site
Volgograd, Russian Federation, 400131
Serbia
Site
Belgrade, Serbia, 11000
Site
Belgrade, Serbia, 11080
Site
Kragujevac, Serbia, 34000
Site
Sremska Kamenica, Serbia, 21204
Spain
Site
Barcelona, Spain, 8035
Site
Barcelona, Spain, 8041
Site
Barcelona, Spain, 8908
Site
Córdoba, Spain, 14004
Site
El Palmar, Spain, 46010
Site
Elche, Spain, 3203
Site
Girona, Spain, 17007
Site
Madrid, Spain, 28046
Site
Madrid, Spain, 28050
Site
Málaga, Spain, 29010
Site
Palma De Mallorca, Spain, 7120
Site
Palma De Mallorca, Spain, 7198
Site
Sabadell, Spain, 8208
Site
Seville, Spain, 41013
Site
Valencia, Spain, 46009
Site
Valencia, Spain, 46010
Site
Zaragoza, Spain, 50009
Taiwan
Site
Taichung, Taiwan, 40705
Site
Tainan, Taiwan, 704
Site
Taipei, Taiwan, 10002
Site
Taipei, Taiwan, 10630
Site
Taipei, Taiwan, 11259
Site
Taoyuan, Taiwan, 3331
Ukraine
Site
Chernivtsi, Ukraine, 58013
Site
Dnepropetrovsk, Ukraine, 49102
Site
Ivano-Frankivs'k, Ukraine, 76018
Site
Kharkiv, Ukraine, 61070
Site
Khmelnytskyi, Ukraine, 29009
Site
Luts'k, Ukraine, 43018
Site
Poltava, Ukraine, 36011
Site
Ternopil', Ukraine, 46000
Site
Vinnytsia, Ukraine, 21029
Site
Zaporizhzhya, Ukraine
Sponsors and Collaborators
Advaxis, Inc.
Gynecologic Oncology Group
Investigators
Layout table for investigator information
Principal Investigator: Thomas J Herzog, MD University of Cincinnati
Principal Investigator: Brian Slomovitz, MD Sylvester Comprehensive Cancer Center

Layout table for additonal information
Responsible Party: Advaxis, Inc.
ClinicalTrials.gov Identifier: NCT02853604     History of Changes
Other Study ID Numbers: ADXS001-02
First Posted: August 3, 2016    Key Record Dates
Last Update Posted: March 5, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female